Over the past four years, research has deepened the understanding of the relationship between COVID-19 and dermatologic conditions like psoriasis. Recent studies have focused on the impact of COVID-19 infection and vaccination on psoriasis. Some studies investigated psoriasis exacerbation post-vaccination, considering patient characteristics and timing of flare ups, and found no significant connection with biological treatments. Another systematic review studied psoriasis flare-ups post-COVID-19 vaccination, noting varying onset times and a predominance of cases in individuals with a history of psoriasis, with Pfizer’s vaccine most frequently implicated.
Research on the impact of biologics on patients with psoriasis with COVID-19 showed increased disease severity post-infection, but those treated with certain biologics like IXE exhibited less exacerbation. Finally, a multicenter study in China assessed COVID-19 incidence and mortality among patients with psoriasis, revealing that IL-23 inhibitor treatment decreased COVID-19 risk, with outdoor workers and patients with other allergic diseases also showing reduced infection rates.
Reference: Andrus E. Exploring the Link Between COVID-19 Research and Psoriatic Disease. Dermatology Times. Published March 19, 2024. Accessed April 8, 2024. https://www.dermatologytimes.com/view/exploring-the-link-between-covid-19-research-and-psoriatic-disease
